Tremfya

(guselkumab)
Tremfya 100 MG in 1 ML Auto-InjectorTremfya 100 MG in 1 ML Prefilled Syringe
NO BOXED WARNING

Dosage & administration

Plaque Psoriasis

100 mg administered by subcutaneous injection at Week 0, Week 4 and every 8 weeks thereafter. ( 2.1)

Psoriatic Arthritis

100 mg administered by subcutaneous injection at Week 0, Week 4 and every 8 weeks thereafter. TREMFYA can be used alone or in combination with a conventional DMARD (e.g. methotrexate). ( 2.2)

drug label

Tremfya prescribing information

prior authorization

Tremfya prior authorization resources

Most recent Tremfya prior authorization forms

View By Payer
Verified: Feb 07, 2024Kaiser Foundation Health Plan - Chronic High-Dose Opioid Therapy Prior Authorization Form Washington
Verified: Feb 07, 2024Kaiser Permanente - Mid Atlantic Tremfya Prior Authorization Form Mid-Atlantic States
Verified: Mar 02, 2024Highmark BCBS Northeastern NY - Medicare Prescription Drug Medication Request Form
Verified: Mar 02, 2024Highmark BCBS Northeastern NY - Short Acting Opioid Prior Authorization Form
Verified: Mar 02, 2024Highmark BCBS Western NY - Specialty Drug Prior Authorization Form

Most recent state uniform prior authorization forms

Verified: Feb 27, 2024Arizona - Uniform Prior Authorization Form
Verified: Feb 27, 2024Colorado - Uniform Prior Authorization Form
Verified: Feb 27, 2024Hawaii - Uniform Prior Authorization Form
Verified: Feb 27, 2024Illinois - Uniform Prior Authorization Form
Verified: Feb 27, 2024Indiana - Uniform Prior Authorization Form
Verified: Feb 27, 2024Louisiana - Uniform Prior Authorization Form
Verified: Feb 27, 2024Michigan - Uniform Prior Authorization Form
Verified: Feb 27, 2024Minnesota - Uniform Prior Authorization Form
Verified: Feb 27, 2024New Hampshire - Uniform Prior Authorization Form
Verified: Feb 27, 2024New Mexico - Uniform Prior Authorization Form
Verified: Feb 27, 2024Oregon - Uniform Prior Authorization Form
Verified: Feb 27, 2024Texas - Uniform Prior Authorization Form
Complete Letter of Medical Necessity
Coverage Authorization Appeals
Letter of Medical Necessity (Reverification)
PA Checklist
PA Checklist - Spanish
Formulary Exceptions Checklist
Formulary Exceptions Checklist - Spanish
Formulary Exception Letter
Appeals Checklist
Appeals Checklist - Spanish
Learn More

Benefits investigation

Patient Authorization Form - To be Signed by Patient if HCP Office has no BAA with Janssen
Tremfya With Me Enrollment & Prescription Form
Learn More

pharmacy

Tremfya preferred pharmacy

Pharmacy List

financial assistance

Tremfya financial assistance options

Co-pay savings program

commercial only
Patient Authorization Form - To be Signed by Patient if HCP Office has no BAA with Janssen
Tremfya With Me Enrollment & Prescription Form
Enroll in Patient Savings Program
Rebate Form (If Pharmacy Unable to Process Savings Card)
Learn More

Bridge program

commercial only
Tremfya With Me Enrollment & Prescription Form
Bridge Program
Learn More

Foundation programs

under insured
no insurance
goverment insurance
65+
Patient Authorization Form - To be Signed by Patient if HCP Office has no BAA with Janssen
Johnson & Johnson Patient Assistance Foundation (JJPAF) Eligibility Check
Learn More

PubMed™ | Tremfya

Tremfya PubMed™ News

patient education

Tremfya patient education

Getting started on Tremfya

Instructions For Use: Plaque Psoriasis
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Instructions For Use: Psoriatic Arthritis
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
To share resource; ask patient to:
1.Pull out phone
2.Open camera
3.Scan QR code with camera
4.Tap link

Patient toolkit

Patient Brochure: Psoriatic Arthritis
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
About Tremfya: Plaque Psoriasis
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
View How to Take Tremfya: Plaque Psoriasis
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
About Tremfya: Psoriatic Arthritis
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
View How to Take Tremfya: Psoriatic Arthritis
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Learn More

Other resources

Sharps Container
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Learn More

people also ask

Tremfya FAQs

Is TREMFYA safe to use during pregnancy?There are no available data on TREMFYA use in pregnant women to inform a drug associated risk of adverse developmental outcomes. Human IgG antibodies are known to cross the placental barrier; therefore, TREMFYA may be transmitted from the mother to the developing fetus. In a combined embryofetal development and pre- and post-natal development study, no adverse developmental effects were observed in infants born to pregnant monkeys after subcutaneous administration of guselkumab during organogenesis through parturition at doses up to 30 times the maximum recommended human dose (MRHD). Neonatal deaths were observed at 6- to 30-times the MRHD. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. Pregnant women should discuss the potential risks and benefits of TREMFYA with their healthcare provider.
Is there a pregnancy exposure registry for TREMFYA?Yes, there is a pregnancy registry that monitors pregnancy outcomes in women exposed to TREMFYA during pregnancy. Patients should be encouraged to enroll by calling 1-877-311-8972.
What is the estimated background risk of major birth defects and miscarriage in the general population?In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.
What animal data is available for TREMFYA use during pregnancy?In a combined embryofetal development and pre- and post-natal development study, pregnant cynomolgus monkeys were administered weekly subcutaneous doses of guselkumab up to 50 mg/kg (30 times the MRHD based on a mg/kg comparison) from the beginning of organogenesis to parturition. Neonatal deaths occurred in the offspring of one control monkey, three monkeys administered guselkumab at 10 mg/kg/week (6 times the MRHD based on a mg/kg comparison) and three monkeys administered guselkumab at 50 mg/kg/week (30 times the MRHD based on a mg/kg comparison). The clinical significance of these findings is unknown. No guselkumab-related effects on functional or immunological development were observed in the infants from birth through 6 months of age.
What are the risks associated with guselkumab use during lactation?There is no data on the presence of guselkumab in human milk or the effects on the breastfed infant or milk production. Maternal IgG is known to be present in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for TREMFYA and any potential adverse effects on the breastfed infant from TREMFYA or from the underlying maternal condition.
Is TREMFYA safe and effective for use in pediatric patients?The safety and efficacy of TREMFYA in pediatric patients (less than 18 years of age) have not been established.
Are there differences in safety or effectiveness of TREMFYA in geriatric patients?No overall differences in safety or effectiveness were observed between older and younger subjects who received TREMFYA. However, the number of subjects aged 65 years and older was not sufficient to determine whether they respond differently from younger subjects.
FAQ Data Source